Gemfibrozil (Pharmacor)™

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

PHARMACOR GEMFIBROZIL 600 is indicated as an adjunct to diet and other therapeutic measures for: Severe hypertriglyceridaemia (Type IV and V) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Dyslipidaemia associated with diabetes. Reduction of risk of coronary heart disease in patients with Type IIa and IIb hypercholesterolaemia. Because of potential toxicity such as malignancy, gallbladder disease, abdominal pain leading to appendectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with chemically and pharmacologically related drug, clofibrate, the potential benefits of gemibrozil in treating Type IIa patients with elevations of LDL-cholesterol only is not likely to outweigh the risks. In a subgroup analysis of patients in the Helsinki Heart Study with above median HDL-cholesterol values at baseline (greater than 1.2mmol/L), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. NOTE: PHARMACOR GEMFIBROZIL 600 IS INDICATED WHEN EXERCISE, WEIGHT LOSS AND SPECIFIC DIETARY OR OTHER NON-DRUG MEASURES SUCH AS LIMITING ALCOHOL INTAKE HAVE FAILED. OTHER MEDICAL DISORDERS SUCH AS HYPOTHYROIDISM AND DIABETES SHOULD BE CONTROLLED AS MUCH AS POSSIBLE. PERIODIC DETERMINATION OF SERUM LIPIDS SHOULD BE OBTAINED DURING TREATMENT WITH PHARMACOR GEMFIBROZIL 600. THE DRUG SHOULD BE WITHDRAWN OR ADDITIONAL THERAPY INSTITUTED IF THE LIPID RESPONSE IS DEEMED INADEQUATE AFTER THREE MONTHS.,PHARMACOR GEMFIBROZIL 600 is indicated as an adjunct to diet and other therapeutic measures for: Severe hypertriglyceridaemia (Type IV and V) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Dyslipidaemia associated with diabetes. Reduction of risk of coronary heart disease in patients with Type IIa and IIb hypercholesterolaemia. Because of potential toxicity such as malignancy, gallbladder disease, abdominal pain leading to appendectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with chemically and pharmacologically related drug, clofibrate, the potential benefits of gemfibrozil in treating Type IIa patients with elevations of LDL-cholesterol only is not likely to outweigh the risks. In a subgroup analysis of patients in the Helsinki Heart Study with above median HDL-cholesterol values at baseline (greater than 1.2mmol/L), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. NOTE: PHARMACOR GEMFIBROZIL 600 IS INDICATED WHEN EXERCISE, WEIGHT LOSS AND SPECIFIC DIETARY OR OTHER NON-DRUG MEASURES SUCH AS LIMITING ALCOHOL INTAKE HAVE FAILED. OTHER MEDICAL DISORDERS SUCH AS HYPOTHYROIDISM AND DIABETES SHOULD BE CONTROLLED AS MUCH AS POSSIBLE. PERIODIC DETERMINATION OF SERUM LIPIDS SHOULD BE OBTAINED DURING TREATMENT WITH PHARMACOR GEMFIBROZIL 600. THE DRUG SHOULD BE WITHDRAWN OR ADDITIONAL THERAPY INSTITUTED IF THE LIPID RESPONSE IS DEEMED INADEQUATE AFTER THREE MONTHS.

Source: ARTG

• Shelf lifetime is 3 Years
• Store below 25 degrees Celsius
• Protect from Moisture

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Tablet, film coated
• Oral
• White to off-white, oval, biconvex, film-coated tablet. Engraved APO & 034 with bisect score on one side, 600 on the other side.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 60 tablets

Source: ARTG

This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.

Source: PBS

For the active ingredient: Gemfibrozil

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).